Vir Biotechnology, Inc.
VIR
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 fā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$5.63
Price+2.93%
$0.16
1Y
Price
Market Cap
$783.210m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-9754.3%
EBITDA Margin-9139.9%
Net Profit Margin-10111.8%
Free Cash Flow MarginRevenue
$16.666m
-77.5%
1y CAGR-62.0%
3y CAGR-35.1%
5y CAGREarnings
-$550.229m
-5.4%
1y CAGR-69.8%
3y CAGR-53.0%
5y CAGREPS
-$4.00
-4.4%
1y CAGR-69.2%
3y CAGR-52.7%
5y CAGRBook Value
$947.472m
$1.193b
Assets$245.060m
Liabilities$93.405m
DebtDebt to Assets
7.8%
-0.2x
Debt to EBITDAFree Cash Flow
-$466.380m
-2.8%
1y CAGR-36.5%
3y CAGR+572.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company